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The boomslang (Dispholidus typus) is a 
rear-fanged arboreal snake of the colubrid 
family that may cause fatal envenomation. 
An unremarkable bite may cause a serious 
venom-induced consumptive coagulopathy 
(VICC) through the proposed activation 
of clotting factor II (prothrombin), factor 
X, and possibly factor IX (Fig. 1).[1,2] In 
addition to prothrombin activation, several 
other mechanisms have been proposed that 
contribute to the clinical envenomation 
syndrome.[3] In contrast, the anticoagulant 
medication warfarin reduces the functional 
pool of vitamin K-dependent clotting factors 
II, VII, IX and X by inhibiting the vitamin K 
epoxide reductase C1 (VKORC1) enzyme to 
produce the anticoagulant effect.[4] Few cases 
of boomslang bite have been described in the 
literature, and the interaction of boomslang 
venom with warfarin on the coagulation 
system is unknown.[5-14] To our knowledge, 
this is the first description of boomslang 
envenomation in a patient on warfarin 
therapy.
Case report
A 45-year-old white man from Northern 
Cape Province, South Africa, was bitten by 
a snake on the left hand while trimming 
a hedge (Fig. 2). He applied a tourniquet 
to the left forearm, and took photos of the 
snake. He presented to medical services 
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The venom of the boomslang (Dispholidus typus) has potent effects on the coagulation system. It is known to produce a venom-induced 
consumptive coagulopathy (VICC) through the proposed activation of clotting factor II (prothrombin), factor X, and possibly factor IX. 
Warfarin, an anticoagulant medication, decreases the circulating vitamin K-dependent clotting factors II, VII, IX and X. We report a 
unique case of a boomslang bite in a patient on warfarin therapy. During the patient’s hospital stay he developed abnormal clotting profiles 
indicating an underlying VICC, but without major bleeding. He received monovalent antivenom and recovered with no complications. We 
discuss two possible outcomes of a boomslang bite in a patient on warfarin therapy, exploring the underlying pathophysiology that could 
lead to the presentation of a reduced risk of overall bleeding or, alternatively, that the bleeding could be compounded and exacerbated. It is 
possible that in our case the anticoagulant effect of warfarin was wholly obscured by the VICC of the boomslang venom. The composition 
of the snake venom may have been a contributory factor in the reduced clinical bleeding observed.























Fig. 1. Overview of warfarin and boomslang venom effect on the coagulation cascade. Warfarin (red 
boxes) reduces functional levels of vitamin K-dependent clotting factors II, VII, IX and X. It is thought 
that boomslang venom (green boxes) activates factors II (prothrombin to thrombin), X and IX, leading 
to fibrinogen depletion and consumptive coagulopathy. (PT = prothrombin time; INR = international 
normalised ratio; aPTT = activated partial thromboplastin time.)
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2  hours after the bite, and was transferred to a referral hospital 
(Fig. 3). The snake was subsequently identified from the photos by 
a snake expert as a boomslang. The patient had a notable medical 
history of previous pulmonary embolism requiring warfarin therapy. 
The international normalised ratio (INR) measurements during the 
preceding 9 months had been within the therapeutic range.
On examination there was oozing from the bitemarks and at the 
venepuncture site. No petechiae or ecchymoses were noted, but the 
patient developed a small haematoma over the deltoid area where 
antitetanus toxoid was injected. There were no features of shock, 
disseminated intravascular coagulation or renal failure. The blood 
biochemistry was essentially normal.
The patient remained asymptomatic 5 hours after the bite, despite 
the clotting profile becoming severely deranged (Table 1). The 
attending clinician decided to administer two 10 mL ampoules of 
monovalent boomslang antivenom intravenously 6 hours after the 
bite. Promethazine 25 mg and hydrocortisone 100 mg were also 
administered for prevention of allergic reactions from intravenous 
antivenom immunoglobulins. Shortly after the antivenom infusion 
was initiated, however, the patient developed severe rigors and 
became hypotensive, with a systolic blood pressure of 69 - 80 mmHg 
that was treated with intravenous fluid administration. The 
hypotension slowly resolved within 12 hours, and the patient 
was lucid throughout. He did not receive any interventions to 
treat warfarin toxicity such as vitamin K therapy or replacement 
blood products such as plasma. Follow-up clotting profiles showed 
significant improvement (Table 1), and the patient’s clotting profile 
normalised ~18 hours after antivenom administration. No other 
complications or clinical bleeding were reported. He remained stable 
after antivenom administration and was subsequently discharged on 
day 3.
Informed consent was obtained from the patient for the sharing of 
this information.
Discussion
The boomslang is a slender snake with a short head and 
characteristically large eyes. They are widely distributed in sub-
Saharan Africa. The average adult length is 120 - 155 cm. Most 
boomslang have green colouring, although colours may vary to 
red-black, yellow or brown.[10] They are shy and timid snakes, but 
when cornered inflate the anterior part of the body.[10,15] Typical 
manifestations of envenomation occur 4 - 24 hours after a bite, 
usually as mucosal or dermal bleeds, or bleeding from sites of 
iatrogenic skin penetration. Severe VICC may lead to intracranial 
haemorrhage and multiple organ failure.[15]
The major component of boomslang venom causing VICC is 
reported to be PIII snake-venom metalloproteases (SVMPs), acting 
as a coagulant disruptor.[3,16] Boomslang venom exerts further 
coagulopathic effects via platelet disruption from disintegrins (also 
SVMPs) and phospholipase A2. Additional postulated mechanisms 
include vessel wall disruption through proteolytic enzymes such 
as three-finger toxin and cysteine-rich secretory protein.[3] Tissue 
factors, vascular pores and vascular permeability may also affect the 
clinical course of envenomation. It is therefore not possible to predict 
the exact clinical outcome in advance, as venom composition can vary 
by region and be affected by the snake’s diet and age.[3] Boomslang 
antivenom is a monovalent, equine-derived immunoglobulin that 
binds to and causes neutralisation of the toxins in the venom.[15,17] 
This process is thought to prevent further binding of the toxin to 
various tissues and halts the VICC process.[1]
Boomslang venom and warfarin may have potentially interacting 
effects on coagulation and clinical bleeding based on their respective 
mechanisms of action. Two scenarios may be considered: firstly, 
overall bleeding is reduced, or secondly, bleeding is compounded 
and exacerbated. The first scenario stems from the rationale that 
the mechanism of anticoagulation induced by warfarin is mediated 
through the reduction of functional levels of vitamin K-dependent 
clotting factors. This reduction may paradoxically have a protective 
Fig. 2. The unremarkable bite site on the left hand of the patient, with some 
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Fig. 3. Timeline of the clinical course of envenomation. Green boxes depict administration of medications.
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function, as there may be fewer functional clotting factors available 
for the boomslang venom to activate, with an attenuated VICC 
response. Evidence for this proposed mechanism was described 
using venom from the pit viper Bothrops jararaca, with a similar 
coagulopathic presentation to the boomslang. Researchers depleted 
VKDCF in rats using warfarin and, after administration of the 
venom, showed that VICC was biochemically reduced compared with 
un-warfarinised controls.[18] In humans, therapeutic doses of warfarin 
reduce levels of clotting factors II and X to 20 - 40% and 15 - 25% of 
baseline levels, respectively.[19,20] This reduction correlates clinically 
with an INR of 2 - 3, which is considered the desired range for most 
indications for warfarin. Above this INR range the probability of 
bleeding is more likely, and a critical threshold is reached where the 
level of clotting factors and the INR no longer correlate.[20]
The second scenario assumes that although warfarin reduces 
the amount of functional clotting factors available, the remaining 
factors may still be activated by the boomslang venom. This may 
result in an even greater depletion of the remaining VKDCF, and an 
augmented VICC. The clinical implication is a significantly increased 
risk of bleeding. The underlying mechanisms predicting clinical 
bleeding are, however, undoubtedly more complex. A variation in 
composition, such as more SVMP coagulant disruptors and fewer 
blood vessel disruptors, may explain the severely deranged clotting 
profile and lack of significant clinical bleeding observed in our case.
Either of the above scenarios may hold true in our case: the 
first scenario has potential in that the patient did not develop 
evident clinical features prior to administration of the antivenom, 
although it is well documented that boomslang envenomation 
may have a significant delay in the presentation of overt clinical 
features. [11] Nevertheless, rapid deterioration in some patients has 
been reported,[7] but was not observed in this case despite the 
severely deranged clotting profile. The patient’s clotting profile 
supports the second scenario more strongly: the INR and activated 
partial thromboplastin time were significantly increased, presumably 
indicating involvement of the extrinsic, intrinsic and common 
pathways of the coagulation cascade. Fibrinogen degradation 
products were also significantly raised, indicating that a process 
of consumptive coagulopathy did indeed occur despite warfarin 
reducing the number of functional clotting factors. However, 
considering that the patient did not develop signs and symptoms of 
overt clinical bleeding, it is reasonable to consider that the effect of 
warfarin on the coagulation cascade was possibly overcome by the 
effects of the boomslang venom. Possible reasons for the presentation 
may have been that the composition of the snake venom affected 
intravascular coagulation more than blood vessel disruption, or that 
the time from envenomation to antivenom administration was too 
short for significant clinical bleeding to occur.
Conclusions
This unique case description provides insight into the underlying 
mechanisms of the interaction of warfarin and boomslang venom. 
It is likely that in this case the anticoagulant effect of warfarin was 
overridden by the VICC of the boomslang venom, and that the 
boomslang’s venom composition contributed to the fact that the 
patient did not develop major bleeding before the administration of 
antivenom. Meticulous recording of similar rare cases may validate 
the abovementioned theories, and clinicians may thus be equipped to 
manage such patients well. Further research is needed to elucidate the 
pathophysiology of the interaction.
Teaching points
• A boomslang bite may cause an acute venom-induced consump-
tive coagulopathy through the proposed activation of clotting 
factors II, X and possibly IX.
• In contrast, warfarin reduces the functional pool of vitamin 
K-dependent clotting factors II, VII, IX and X by inhibiting the 
VKORC1 enzyme to produce the anticoagulant effect.
• Boomslang venom and warfarin may have potentially interacting 
effects on coagulation and clinical bleeding based on their 
respective mechanisms of action.
• Individual snake venom composition may alter the clinical 
presentation.
• Boomslang antivenom is an effective antidote.
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